The Maryland Prescription Drug Affordability Board has taken a significant step towards making the Ozempic diabetes treatment more affordable for residents. The board has agreed to set an upper payment limit for the type 2 diabetes medicine, marking the second time it has taken such a measure in recent weeks. This move is expected to have a positive impact on the state and local governments, as well as residents who rely on the medication.
The board, which functions like a state utility commission, will oversee the process to lower the cost of Ozempic. By January 2027, the price of the medication will be capped at $274 for a 30-day supply. According to estimates, this move will result in annual savings of $5.8 million. The expected cost was benchmarked against the maximum fair price paid by Medicare, as stated by Andrew York, the executive director of the Maryland board.
The decision to set a price cap on Ozempic is a crucial step towards making healthcare more affordable for Maryland residents. The board's efforts to lower the cost of high-cost drugs will have a significant impact on the state's healthcare system. By taking a proactive approach to addressing the issue of expensive medications, the board is working to ensure that residents have access to the treatments they need without breaking the bank.
The Maryland Prescription Drug Affordability Board is expected to continue its efforts to make healthcare more affordable in the coming years. In 2028, the board is expected to begin acting to set upper payment limits on high-cost drugs purchased by all Marylanders in the commercial insurance market. This move will further expand the board's efforts to make healthcare more accessible and affordable for all residents, regardless of their insurance status. As the board continues to work towards its goals, it is likely that more medications will be subject to price caps, leading to significant savings for residents and the state as a whole.
